BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1838364)

  • 21. [Renal toxicity of high-dose methotrexate].
    Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal impairment following the combined use of high-dose methotrexate and procarbazine.
    Price P; Thompson H; Bessell EM; Bloom HJ
    Cancer Chemother Pharmacol; 1988; 21(3):265-7. PubMed ID: 3359561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe renal toxicity due to intermediate-dose methotrexate.
    Stark AN; Jackson G; Carey PJ; Arfeen S; Proctor SJ
    Cancer Chemother Pharmacol; 1989; 24(4):243-5. PubMed ID: 2546688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Managing methotrexate toxicity: a case report].
    Fernández Megía MJ; Alós Almiñana M; Terol Castera MJ
    Farm Hosp; 2004; 28(5):371-4. PubMed ID: 15504095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of methotrexate administration following 5-fluorouracil.
    White RM
    Am J Clin Oncol; 1996 Oct; 19(5):492-9. PubMed ID: 8823478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
    Chan BS; Dawson AH; Buckley NA
    Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].
    Sauer H; Schalhorn A
    Onkologie; 1980 Apr; 3(2):64-71. PubMed ID: 6994007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding and managing methotrexate nephrotoxicity.
    Widemann BC; Adamson PC
    Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study.
    Dady PJ; Taylor GA; Muindi JF; Calvert AH; Smith IE; Smyth JF; Harrap KR
    Cancer Treat Rep; 1981; 65 Suppl 1():37-43. PubMed ID: 7326664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.
    Krause AS; Weihrauch MR; Bode U; Fleischhack G; Elter T; Heuer T; Engert A; Diehl V; Josting A
    Leuk Lymphoma; 2002 Nov; 43(11):2139-43. PubMed ID: 12533039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity associated with combination chemotherapy for osteosarcoma: a report of the cooperative osteosarcoma study (COSS 80).
    Jürgens H; Beron G; Winkler K
    J Cancer Res Clin Oncol; 1983; 106 Suppl():14-8. PubMed ID: 6350313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low prevalence of high-dose methotrexate nephropathy in patients with malignancy.
    Mashhadi MA; Kaykhaei MA; Sanadgol H
    Iran J Kidney Dis; 2012 Mar; 6(2):105-9. PubMed ID: 22388607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
    Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
    Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose leucovorin as sole therapy for methotrexate toxicity.
    Flombaum CD; Meyers PA
    J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
    Sadée W
    Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen.
    Thyss A; Milano G; Kubar J; Namer M; Schneider M
    Lancet; 1986 Feb; 1(8475):256-8. PubMed ID: 2868265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic methotrexate toxicity. A pharmacological study of its occurrence after intrathecal administration in a patient with renal failure.
    Cadman EC; Lundberg WB; Bertino JR
    Arch Intern Med; 1976 Nov; 136(11):1321-2. PubMed ID: 990053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.